Abstract
We read the recent study by Ali and associates. 1 Ali T.K. Gibbons A. Cartes C. et al. Use of autologous serum tears for the treatment of ocular surface disease from patients with systemic autoimmune diseases. Am J Ophthalmol. 2018; 189: 65-70 Abstract Full Text Full Text PDF PubMed Scopus (14) Google Scholar The article addressed an interesting topic, but there are some drawbacks, as outlined below. Use of Autologous Serum Tears for the Treatment of Ocular Surface Disease From Patients With Systemic Autoimmune DiseasesAmerican Journal of OphthalmologyVol. 189PreviewTo describe the safety and efficacy of autologous serum tears (AST) in managing ocular surface disease resistant to conventional therapy in patients with systemic autoimmune disease(s). Full-Text PDF
Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
